Protection of myocardium with trimetazidine during elective endovascular treatment for ischemic heart disease in patients with disturbed carbohydrate metabolism

2015 ◽  
Vol 14 (4) ◽  
pp. 187-192
Author(s):  
E.O. Vershinina ◽  
◽  
A.N. Repin ◽  
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Endovascular Treatment ◽  
Carbohydrate Metabolism ◽  
Ischemic Heart

Abstract TP36: Predictors and Associated Outcomes of Subarachnoid Hemorrhage Following Endovascular Treatment for Acute Ischemic Stroke

Stroke ◽  
2016 ◽  
Vol 47 (suppl_1) ◽  
Author(s):  
Alexandros L Geordiadis ◽  
Muhammad A Saleem ◽  
Adnan I Qureshi
Keyword(s):  
Heart Disease ◽  
Subarachnoid Hemorrhage ◽  
Ischemic Heart Disease ◽  
Endovascular Treatment ◽  
Univariate Analysis ◽  
Prospective Trial ◽  
Endovascular Intervention ◽  
Ischemic Heart ◽  
History Of ◽  
Stroke Trial

Introduction: The rates of occurrence, predictors, and associated outcomes of subarachnoid hemorrhage (SAH) following endovascular treatment are not well studied. Methods: We retrospectively analyzed data from the Interventional Management of Stroke Trial (IMS III). This prospective trial randomized patients to intravenous (IV) rt-PA alone versus IV rt-PA followed by endovascular intervention. All patients underwent computed tomography (CT) at 24 hours post randomization. The scans were assessed by independent reviewers at a core laboratory for the presence, location, and type of intracranial hemorrhage.The primary outcome assessment was by modified Rankin Scale (mRS) score at 3 months. Results: Thirty four out of 434 (7.8%) patients who received endovascular treatment suffered SAH at 24 hours. There were 19 men (55.9%), and 19 patients were older than 70 years.In univariate analysis only pre-existing ischemic heart disease was identified as a predictor of SAH (p=0.03) while patient age was borderline significant (p=0.055). Three-monthmRS score was available for 24/34 patients with SAH and for 318/400 among the other patients. There was no difference in mortality (12.5% vs. 4.1%, p=0.167) or favorable outcome defined as mRS =<2 (41.7% vs. 53.5%, p=0.366). Conclusions: SAH following endovascular intervention for acute stroke is more common among patients with history of ischemic heart disease. It does not impact on functional outcome or mortality at 3 months.

scholarly journals Comparative characteristics of coated stents used in endovascular treatment of patients with coronary heart disease

2015 ◽  
Vol 17 (1) ◽  
pp. 91
Author(s):  
A. G. Osiev ◽  
S. P. Mironenko ◽  
D. S. Yelkina
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Endovascular Treatment ◽  
Ischemic Heart ◽  
Drug Eluting Stents ◽  
Chronic Ischemic Heart Disease ◽  
Drug Eluting

A comparison of characteristics of drug-eluting stents used in endovascular treatment of patients with chronic ischemic heart disease was carried out. The efficacy of sirolimus stents coated with paclitaxel and their influence on the process of restenosis was evaluated.

scholarly journals Late results of transcutaneous coronary intervention in patients, suffering ischemic heart disease and diabetes mellitus

2018 ◽  
Vol 85 (4) ◽  
pp. 19-21
Author(s):  
G. B. Mankovsky
Keyword(s):  
Diabetes Mellitus ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Carbohydrate Metabolism ◽  
Balloon Angioplasty ◽  
Coronary Intervention ◽  
Late Results ◽  
Ischemic Heart

Objective. Estimation of late results of transcutaneous coronary intervention (TCCI) in patients, suffering іschemic heart disease (ІHD) and diabetes mellitus (DM). Маterials and methods. Results of questionnaires application in 459 patients were analyzed. Results. After TCCI performance in patients, suffering IHD and DM, the angina recurrences have occurred more often, аs well as the necessity to reperform coronarography and TCCI, comparing to patients without disorders of carbohydrate metabolism. Presence of DM in patients, suffering ІHD, did not impact on the reintervention rate after doing TCCI , using stents with medicinal coverage. After doing the balloon angioplasty or implantation of stents without medicinal coverage in patients, suffering ІHD and DM, a necessity for reoperation, using TCCI, have occurred trustworthily more often. Conclusion. Balloon angioplasty or implantation of stents without medicinal coverage in the patients, suffering ІHD and DM, results in the risk enhancement for restenosis occurrence, comparing with patients, in whom DM is absent. DM trustworthily do not lead to enhancement of the restenosis risk, while doing a primary TCCI, using stents with medicinal coverage.

Sign in / Sign up

Export Citation Format

Share Document